Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.

Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...

Everest Medicines has dosed the first subject with EVM16, the company’s personalised mRNA cancer vaccine, in the EVM16CX01 ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

The US FDA has ordered BioNTech to immediately halt its Phase I/II trial of BNT165e, a malaria vaccine candidate, pending ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial.

Subjects in the fourth cohort will receive a dose nearly 50% higher than the previous cohort. Credit: Amnaj Khetsamtip/Shutterstock. The Safety Review Committee (SRC) has granted unanimous approval ...